139 related articles for article (PubMed ID: 36821942)
1. Downregulation of Polo-like kinase 4 induces cell apoptosis and G2/M arrest in acute myeloid leukemia.
Chen S; Zhong L; Chu X; Wan P; Liu Z; Lu Y; Zhang Z; Wang X; Zhou Z; Shao X; Liu B
Pathol Res Pract; 2023 Mar; 243():154376. PubMed ID: 36821942
[TBL] [Abstract][Full Text] [Related]
2. Effects of the PLK4 inhibitor Centrinone on the biological behaviors of acute myeloid leukemia cell lines.
Mu XR; Ma MM; Lu ZY; Liu J; Xue YT; Cao J; Zeng LY; Li F; Xu KL; Wu QY
Front Genet; 2022; 13():898474. PubMed ID: 36051696
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of PLK4 expression induces apoptosis and G0/G1-phase cell cycle arrest in keloid fibroblasts.
Huang RL; Liu C; Fu R; Yan Y; Yang J; Wang X; Li Q
Cell Prolif; 2022 Jul; 55(7):e13271. PubMed ID: 35670224
[TBL] [Abstract][Full Text] [Related]
4. Activating transcription factor 6 (ATF6) negatively regulates Polo-like kinase 4 expression via recruiting C/EBPβ to the upstream-promoter during ER stress.
Shen T; Li Y; Chen Z; Liang S; Qiu Y; Zhu L; Ba G; Lu G; Qiu L
Biochim Biophys Acta Gene Regul Mech; 2020 Feb; 1863(2):194488. PubMed ID: 31926341
[TBL] [Abstract][Full Text] [Related]
5. PLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt/β-catenin pathway in anaplastic thyroid cancer.
Zhu W; Xie B
Cancer Biol Ther; 2023 Dec; 24(1):2223383. PubMed ID: 37351847
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of diacylglycerol kinase zeta (DGKZ) induces apoptosis and G2/M phase arrest in human acute myeloid leukemia HL-60 cells through MAPK/survivin/caspase pathway.
Li H; Dong C; Tian Y; Li X; Wang B; Zhai D; Bai Y; Chao X
Pharmazie; 2019 Jul; 74(7):418-422. PubMed ID: 31288898
[TBL] [Abstract][Full Text] [Related]
7. Use of the Polo-like kinase 4 (PLK4) inhibitor centrinone to investigate intracellular signalling networks using SILAC-based phosphoproteomics.
Byrne DP; Clarke CJ; Brownridge PJ; Kalyuzhnyy A; Perkins S; Campbell A; Mason D; Jones AR; Eyers PA; Eyers CE
Biochem J; 2020 Jul; 477(13):2451-2475. PubMed ID: 32501498
[TBL] [Abstract][Full Text] [Related]
8. RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
Kolosenko I; Goroshchuk O; Vidarsdottir L; Björklund AC; Dowdy SF; Palm-Apergi C
FASEB J; 2021 May; 35(5):e21476. PubMed ID: 33788972
[TBL] [Abstract][Full Text] [Related]
9. The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia.
Nakamura S; Hirano I; Okinaka K; Takemura T; Yokota D; Ono T; Shigeno K; Shibata K; Fujisawa S; Ohnishi K
Carcinogenesis; 2010 Nov; 31(11):2012-21. PubMed ID: 20823107
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol synergizes with cisplatin in antineoplastic effects against AGS gastric cancer cells by inducing endoplasmic reticulum stress‑mediated apoptosis and G2/M phase arrest.
Ren M; Zhou X; Gu M; Jiao W; Yu M; Wang Y; Liu S; Yang J; Ji F
Oncol Rep; 2020 Oct; 44(4):1605-1615. PubMed ID: 32945472
[TBL] [Abstract][Full Text] [Related]
11. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.
Lei Q; Xiong L; Xia Y; Feng Z; Gao T; Wei W; Song X; Ye T; Wang N; Peng C; Li Z; Liu Z; Yu L
Cell Death Dis; 2018 Oct; 9(11):1066. PubMed ID: 30337519
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of Polo-like kinase 4 (PLK4) induces G1 arrest via activation of the p38/p53/p21 signaling pathway in bladder cancer.
Yang Z; Sun H; Ma W; Wu K; Peng G; Ou T; Wu S
FEBS Open Bio; 2021 Sep; 11(9):2631-2646. PubMed ID: 34342940
[TBL] [Abstract][Full Text] [Related]
13. Autophosphorylation of polo-like kinase 4 and its role in centriole duplication.
Sillibourne JE; Tack F; Vloemans N; Boeckx A; Thambirajah S; Bonnet P; Ramaekers FC; Bornens M; Grand-Perret T
Mol Biol Cell; 2010 Feb; 21(4):547-61. PubMed ID: 20032307
[TBL] [Abstract][Full Text] [Related]
14. Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing's sarcoma cells.
Kerschner-Morales SL; Kühne M; Becker S; Beck JF; Sonnemann J
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2871-2883. PubMed ID: 32770382
[TBL] [Abstract][Full Text] [Related]
15. YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.
Zhu Y; Liu Z; Qu Y; Zeng J; Yang M; Li X; Wang Z; Su J; Wang X; Yu L; Wang Y
Cancer Chemother Pharmacol; 2020 Jul; 86(1):33-43. PubMed ID: 32519033
[TBL] [Abstract][Full Text] [Related]
16. Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway.
Tian X; Zhou D; Chen L; Tian Y; Zhong B; Cao Y; Dong Q; Zhou M; Yan J; Wang Y; Qiu Y; Zhang L; Li Z; Wang H; Wang D; Ying G; Zhao Q
Cell Death Dis; 2018 Jan; 9(2):54. PubMed ID: 29352113
[TBL] [Abstract][Full Text] [Related]
17. GSK-J4 induces cell cycle arrest and apoptosis via ER stress and the synergism between GSK-J4 and decitabine in acute myeloid leukemia KG-1a cells.
Chu X; Zhong L; Yu L; Xiong L; Li J; Dan W; Ye J; Liu C; Luo X; Liu B
Cancer Cell Int; 2020; 20():209. PubMed ID: 32514253
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-582-3p negatively regulates cell proliferation and cell cycle progression in acute myeloid leukemia by targeting cyclin B2.
Li H; Tian X; Wang P; Huang M; Xu R; Nie T
Cell Mol Biol Lett; 2019; 24():66. PubMed ID: 31844417
[TBL] [Abstract][Full Text] [Related]
19. Autophagy Inhibition Contributes to Apoptosis of PLK4 Downregulation-induced Dormant Cells in Colorectal Cancer.
Tian X; He Y; Qi L; Liu D; Zhou D; Liu Y; Gong W; Han Z; Xia Y; Li H; Wang J; Zhu K; Chen L; Guo H; Zhao Q
Int J Biol Sci; 2023; 19(9):2817-2834. PubMed ID: 37324947
[TBL] [Abstract][Full Text] [Related]
20. PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence.
Singh CK; Denu RA; Nihal M; Shabbir M; Garvey DR; Huang W; Iczkowski KA; Ahmad N
Prostate; 2022 Jun; 82(9):957-969. PubMed ID: 35333404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
